PT-141: Benefits, Dosage & FDA Status
Bremelanotide (Vyleesi)
A melanocortin receptor agonist that works directly on the nervous system to increase sexual desire. The only FDA-approved peptide for sexual dysfunction that acts on the brain rather than vascular system.
FDA Status
FDA-approved for hypoactive sexual desire disorder (HSDD) in women
Typical Dose
1.75 mg subcutaneous, 45 min before activity
Evidence Grade
AStrong RCT or FDA-approved evidence
Half-Life
~2.7 hours
Routes of Administration
subcutaneous
First Synthesized
2003
Clinics Indexed
210 providers have offered PT-141 in our tracked directory.
Mechanism of Action
Cyclic 7-amino-acid melanocortin receptor agonist (primarily MC4R) that activates dopaminergic pathways governing sexual desire.
Key Reported Benefits
- ✓Increased sexual desire
- ✓CNS-mediated arousal
- ✓Works for both sexes (off-label for men)
Benefits listed reflect commonly reported effects from clinical trials and practitioner use. Individual response varies. Evidence-grade A indicates strong rct or fda-approved evidence.
Reported Side Effects
- •Nausea
- •Flushing
- •Headache
- •Transient blood-pressure rise
Contraindications
- ⚠Uncontrolled hypertension
- ⚠Cardiovascular disease
- ⚠Pregnancy
PT-141 vs Other Peptides
Regulatory & Safety Context
FDA status: FDA-approved for hypoactive sexual desire disorder (HSDD) in women
This page is for educational purposes only and does not constitute medical advice. Peptide use outside of an FDA-approved indication should be discussed with a licensed medical professional. Source quality, cold-chain storage, and injection hygiene all materially affect safety outcomes.
See state-by-state legality: US peptide legality by state →
References
Selected primary literature on PT-141. Full PubMed records linked. Additional citations are available on request.
Last reviewed: 2026-04-30
Related Peptides
Melanotan II
C+A non-selective melanocortin agonist (MC1R/MC3R/MC4R) that produces tanning and erection effects. Significant safety concerns including melanoma case reports.
Kisspeptin-10
BA 10-amino-acid neuropeptide that triggers GnRH release. Studied as a more physiologic alternative to hCG/GnRH for fertility, libido, and HPG-axis assessment.
Gonadorelin
ASynthetic GnRH used clinically to stimulate LH/FSH release. In testosterone replacement therapy, used pulsatile to preserve testicular size and fertility instead of hCG.